Latest News and Press Releases
Want to stay updated on the latest news?
-
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing...
-
SOUTH SAN FRANCISCO, Calif., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
-
-- Investigational drug has potential to treat certain MDR gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae (CRE) -- SOUTH SAN FRANCISCO, Calif., Oct. 26, 2017 (GLOBE...
-
-- Presentations emphasize potential role for plazomicin in treating bloodstream infections (BSI) due to carbapenem-resistant Enterobacteriaceae (CRE) as well as potential long-term clinical benefits...
-
Non-dilutive funding to support clinical development of antibacterial candidate for ESBL infections Company expects top-line Phase 1 results in 2017 and initiation of pivotal Phase 3 trial in 2018 ...
-
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing...
-
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
-
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
-
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
-
SOUTH SAN FRANCISCO, Calif., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...